Protalix BioTherapeutics and Chiesi Global Rare Diseases said Friday that Elfabrio, an enzyme replacement therapy to treat Fabry disease, has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Protalix will be eligible to receive a regulatory milestone payment of $25 million if the treatment is approved by the European Commission, the companies said.

Protalix shares were more than 7% higher in recent trading.

Price: 2.26, Change: +0.18, Percent Change: +8.41